A Personalized Remote Radiation-Tracking Vest for At-Home Monitoring of LU-177 DOTATATE Therapy

被引：0
|
作者：
Pierce, Larry [1 ]
Harrison, Robert [1 ]
Vesselle, Hubert [1 ]
Miyaoka, Robert [1 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
来源：
PANCREAS | 2020年 / 49卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：483 / 483
页数：1
相关论文
共 50 条
  • [31] Variation in the absorbed radiation dose and PSA response after serial Lu-177 PSMA radioligand therapy
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Singh, A.
    Shahinfar, M.
    Muller, D.
    Lehmann, C.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S202 - S202
  • [32] Modeling Early Radiation DNA Damage Occurring During 177Lu-DOTATATE Radionuclide Therapy
    Tamborino, Giulia
    Perrot, Yann
    De Saint-Hubert, Marijke
    Struelens, Lara
    Nonnekens, Julie
    De Jong, Marion
    Konijnenberg, Mark W.
    Villagrasa, Carmen
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (05) : 761 - 769
  • [33] Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation Therapy
    Delbart, Wendy
    Karabet, Jirair
    Marin, Gwennaelle
    Penninckx, Sebastien
    Derrien, Jonathan
    Ghanem, Ghanem E.
    Flamen, Patrick
    Wimana, Zena
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (20)
  • [34] Personalized medicine: method of in vitro determination of receptor binding for Lu-177 radio-pharmaceuticals therapy efficacy estimation
    Kalnina, Z.
    Kusins, T.
    Svirksts, K.
    Rubena, E.
    Kovaldins, R.
    Kizane, G.
    Berzina, A.
    Grinbergs, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S579 - S580
  • [35] Exploration of Ga-68 DOTA PET radiomics to predict the absorbed dose of Lu-177 DOTATATE® therapy of midgut neuroendocrine tumors
    Brahmi, S.
    Vallot, D.
    Vija, L.
    Dierickx, L.
    Courbon, F.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 176 - 176
  • [36] Lu-177 DOTATATE therapy for progressive metastatic neuroendocrine tumors: Multidisciplinary team work and role of technologists, nurses, physicists and physicians.
    Copeland, Autumn
    Mertel, Kathleen
    Mohammadi, Seyed
    Steiner, Cindy
    Mannella, Kelly
    Sheetz, Michael
    Muthukrishnan, Ashok
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [37] Peptide Receptor Radionuclide Therapy (Lu-177 DOTATATE) in Progressive Neuroendocrine Tumors (NETs): Potential Predictors of Progression Free Survival (PFS)
    Badawy, Mohmed
    Johnson, Geoffrey B.
    Hobday, Timothy
    Packard, Annie T.
    Jain, Manoj
    Halfdanarson, Thorvardur R.
    Young, Jason R.
    Thorpe, Matthew P.
    Eiring, Rachel A.
    Kendi, Ayse Tuba
    PANCREAS, 2022, 51 (03) : E42 - E42
  • [38] The Use of 68Ga DOTATATE PET/CT for Diagnostic Assessment and Monitoring of 177Lu DOTATATE Therapy in Pituitary Carcinoma
    Novruzov, Fuad
    Aliyev, Jamil A.
    Jaunmuktane, Zane
    Bomanji, Jamshed B.
    Kayani, Irfan
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (01) : 47 - 53
  • [39] Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
    D. Levart
    E. Kalogianni
    B. Corcoran
    N. Mulholland
    G. Vivian
    EJNMMI Physics, 6
  • [40] Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
    Levart, D.
    Kalogianni, E.
    Corcoran, B.
    Mulholland, N.
    Vivian, G.
    EJNMMI PHYSICS, 2019, 6 (1)
12345